It has been argued that skeletal Mg/Ca ratio in echinoderms is mostly governed by Mg2+ and Ca2+ concentrations in the ambient seawater. Accordingly, well-preserved fossil echinoderms were used to reconstruct Phanerozoic seawater Mg2+ /Ca2+ ratio. However, Mg/Ca ratio in echinoderm skeleton can be affected by a number of environmental and physiological factors, the effects of which are still poorly understood. Notably, experimental data supporting the applicability of echinoderms in paleoenvironmental reconstructions remain limited. Here, we investigated the effect of ambient Mg2+ /Ca2+ seawater ratio and diet on skeletal Mg/Ca ratio and growth rate in two echinoid species (Psammechinus miliaris and Prionocidaris baculosa). Sea urchins were tagged with manganese and then cultured in different Mg2+ /Ca2+ conditions to simulate fluctuations in the Mg2+ /Ca2+ seawater ratios in the Phanerozoic. Simultaneously, they were fed on a diet containing different amounts of magnesium. Our results show that the skeletal Mgerent ossicle types, and stereom types within a single ossicle).
Platelet activation, inflammatory reactions and oxidative stress are common pathogenesis of chronic obstructive pulmonary disease (COPD) with pulmonary heart disease (PHD). Mean platelet volume (MPV) and red blood cell distribution width (RDW) form part of the pathomechanisms of these conditions. Here, we investigated whether MPV and RDW can be biomarkers of PHD occurring secondary to COPD.
This was a retrospective study on 229 participants with COPD. Among them, 69 had PHD. Complete blood count (CBC), blood gas analysis, pulmonary function tests and echocardiography were analyzed.
MPV and RDW-standard deviation (RDW-SD) were significantly higher in patients with PHD than in patients without PHD (P≤0.001). MPV and RDW-SD were positively correlated with pulmonary artery pressure (PAP) and the size of the right ventricle (P≤0.05). Multivariate regression analysis showed that the risk of PHD increased 3-fold per unit rise in MPV (OR=2.901, P≤0.001). We observed that the risk of PHD increased 1.5 times per unit rise in RDW-SD (OR=1.371, P≤0.001).The AUC of ROC curve for the combined MPV and RDW-SD in predicting PHD among COPD patients was 0.900 (95％CI 0.846-0．954, P≤0.001), with a sensitivity of 76.8% and a specificity of 99.4%.
Both MPV and RDW-SD were significantly elevated and correlated with disease severity in COPD patients with PHD. A combination of these two parameters presents an effective biomarker of PHD.
Both MPV and RDW-SD were significantly elevated and correlated with disease severity in COPD patients with PHD. A combination of these two parameters presents an effective biomarker of PHD.We synthesized a set of 13 new and earlier described styrylpyridinium compounds (N-alkyl styrylpyridinium salts with bromide or tosylate anions) in order to evaluate antifungal activity against C. BML-284 albicans cells, to assay the possible synergism with fluconazole, and to estimate cytotoxicity to mammalian cells. All compounds were synthesized according to a well-known two-step procedure involving alkylation of γ-picoline with appropriate alkyl bromide and further condensation with substituted benzaldehyde. Compounds with long N-alkyl chains (C18 H37 -C20 H41 ) had no antifungal activity against the cells of all tested C. albicans strains. Other styrylpyridinium compounds were able to inhibit yeast growth at the concentrations of 0.06-16 μg/ml. At fungicidal concentrations, the compound with the CN- group was least toxic to mammalian cells, showed the most effective synergism with fluconazole, and only slightly inhibited the respiration of C. albicans. The compound with the 4'-diethylamino group exhibited the strongest fungicidal properties and effectively blocked the respiration of C. albicans cells. However, toxicity to mammalian cells was also high. Summarizing, the results of our study indicate that styrylpyridinium compounds are promising candidates in the development of new antifungal drugs.HLA-A*30171 differs from HLA-A*30010101 by one nucleotide substitution at position 821 in exon 4.
The aim of this study was to evaluate the levels of serum and gingival crevicular fluid (GCF)human beta-defensin-2 (hBD-2), an antimicrobial peptide that takes roles in inflammatory diseases, in patients with chronic periodontitis (CP).
A total of one hundred and one individuals, 59 controls and 42 patients with CP, participated in this study. Clinical index measurements were recorded during the periodontal examination, and radiographic evaluation was also performed. The serum and gingival crevicular fluid (GCF) samples were taken from all of the participants, and the hBD-2 levels were determined biochemically byenzyme-linked immunosorbent assay (ELISA).
In our study, hBD-2 GCF levels in CP (stages II-IV periodontitis based on the new 2018 classification of periodontal diseases) group (2.77ng/30s) were higher than in theperiodontallyhealthy (2.51ng/30s; p=.047) individuals. In contrast, serum hBD-2 levels in CP (2.92ng/ml) were lower compared with those in healthy controls (7.75ng/ml, p<.001).
Interestingly, our results showed that while higher hBD-2 GCF levels are associated with CP, lower serum hBD-2 levels were detected in CP.
Interestingly, our results showed that while higher hBD-2 GCF levels are associated with CP, lower serum hBD-2 levels were detected in CP.
Using an investigational diet plan based on the Mediterranean diet and the Dietary Approaches to Stop Hypertension diet comprised of substitute ingredients that mimic the average East Asian diet, this study assessed the glycemic benefits in comparison with a food exchange system-based diet in established type2 diabetes patients.
This was a 12-week, open-label randomized clinical trial carried out among 60 Korean adults with type2 diabetes having a median body mass index of 23.5kg/m
. Glycemic benefits in the investigational diet (groupA) were compared with those obtained with a food exchange system-based diet, either in the form of ready meals provided to participants (groupB) or not (groupC). The primary end-point was changes in glycated hemoglobin from baseline to week12.
Changes in glycated hemoglobin (%) from baseline to week12 were -0.97±0.97 in groupA (vs groupB, P=0.085 in the full analysis set, and P=0.028 in the per-protocol set; vs groupC, P=0.030 in the full analysis set and P=0.020 in the per-protocol set), -0.BML-284
Top comments (0)